OCT 11, 2016 07:00 AM PDT
Two Dimensional Liquid Chromatography Applied to the Characterization of Monoclonal Antibodies and Antibody-Drug Conjugates
SPONSORED BY: Agilent Genomics
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
5 18 2618

Speakers:
  • Scientific Director, Research Institute for Chromatography (RIC), Kortrijk, Belgium
    Biography
      Koen Sandra received a PhD degree in Biochemistry from the Ghent University, Belgium in 2005. After his PhD, he joined Pronota, a molecular diagnostics company where he was active in developing analytical platforms for disease biomarker discovery and in setting up external collaborations. In 2008, he joined the Research Institute for Chromatography (RIC), a company that provides chromatographic and mass spectrometric support to the chemical, life sciences and pharmaceutical industries, where he currently holds the position of Scientific Director. He is furthermore co-founder and co-owner of anaRIC, a company that offers a complete range of analytical solutions for characterization, quality control, release and stability testing of biological drugs and of Metablys, an institute performing metabolomics and lipidomics research. As a non-academic scientist, Koen Sandra is author of over 40 highly cited scientific papers and has presented his work at numerous conferences as an invited speaker

    Abstract:
    DATE:  October 11, 2016
    TIME:  7:00am PT, 10:00am ET

    Monoclonal antibodies (mAbs) have emerged as important therapeutics for the treatment of life-threatening diseases. The successes of mAbs have triggered the development of various next generation formats. In oncology, antibody-drug conjugates (ADCs) are particularly promising, since they synergistically combine a specific mAb linked to a biologically active cytotoxic drug via a stable linker. The promise of ADCs is that highly toxic drugs can selectively be delivered to tumor cells thereby substantially lowering side effects as typically experienced with classical chemotherapy.

    Monoclonal antibodies have a complexity far exceeding that of small molecule drugs, hence, unraveling this complexity represents an analytical challenge. This challenge becomes even bigger in case ADCs are considered since the heterogeneity of the initial antibody is superimposed with the variability associated with the cytotoxic drug conjugation strategy. The present webinar will highlight the power of two dimensional liquid chromatography in hyphenation to high resolution mass spectrometry for the characterization of monoclonal antibodies and antibody-drug conjugates. Both multiple heart-cutting LC-LC, applied at protein level, and comprehensive LCxLC, applied at peptide level, will be discussed.

    For Research Use Only. Not for use in diagnostic procedures.

    Learning Objectives:
    • Obtain insight in the complexity associated with monoclonal antibodies and antibody-drug conjugates.
    • Learn about the challenges and strategies associated with the characterization of monoclonal antibodies and antibody-drug conjugates.
    • Learn about the different modes of two dimensional liquid chromatography and its hyphenation to mass spectrometry.

    Show Resources
    Loading Comments...